Methylene Blue and Ozone in Early Sepsis

Methylene Blue and Ozone in Early Sepsis , a Randomized Double Blind Trial

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02910765

Enrollment

Registered

2016-09-22

Start date

2016-10-31

Completion date

2017-04-30

Last updated

2016-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

effects of methylene blue and ozone O3 therapy effects in early sepsis management , and their implications upon outcome

Detailed description

effects of methylene blue on inducible nitric oxide messenger RNA transcription and protein expression are well evident in vasoplegia ,and septic shock . In the same time , ozone O3 therapy is also valuable in immune-modulation in multiple pathologies . our study collaborate both methylene blue and Ozone in early sepsis management , and we will evaluate the global medical progress , ICU stay , Morbidity and mortality

Interventions

DRUGmethylene blue

DRUGozone

OTHERsaline infusion

OTHERoxygen

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* early sepsis Adults patients

Exclusion criteria

* cardiac problems Glucose-6-Phosphate-Dehydrogenase Insufficiency Ozone Allergy Recent Myocardial Infarction Active Hyperthyroidism Thrombocytopenia Pregnancy Contraindications

Design outcomes

Primary

Measure	Time frame
APACHE score	7 days

Secondary

Measure	Time frame
ICU stay	30 days

Contacts

Primary ContactEmad Zarief K. Said, MD

emadzarief@yahoo.com00201007046058

Backup ContactAbdelraheem Elawamy, MD

00201000032655

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026